百奥泰所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：创新药、抗癌治癌、 抗癌药物、生物医药、融资融券等。 截至9月30日，百奥泰股东户数9397.00，较上期减少0.89%；人均流通股44065股，较上期增加0.89%。 2025年1月-9月，百奥泰实现营业收入6.84亿元，同比增长17.57%；归母净利润-2.24亿元，同比增长 38.72%。 11月25日，百奥泰盘中上涨2.15%，截至09:39，报25.63元/股，成交603.33万元，换手率0.06%，总市值 106.13亿元。 资金流向方面，主力资金净流出49.39万元，大单买入49.37万元，占比8.18%，卖出98.75万元，占比 16.37%。 百奥泰今年以来股价涨32.25%，近5个交易日跌1.65%，近20日跌6.43%，近60日跌21.60%。 资料显示，百奥泰生物制药股份有限公司位于广东省广州市国际生物岛螺旋二路18号，成立日期2003年 7月28日，上市日期2020年2月21日，公司主营业务涉及从事创新药和生物类似药的研发、生产业务。主 营业务收入构成为：药品销售业务91.90%，授权许可业务6.55%，代加工 ...

Core Viewpoint - Baiotai (688177.SH) is currently trading at 25.26 yuan, reflecting a decline of 3.07%, and is in a state of share price drop below its initial public offering (IPO) price [1] Group 1: IPO Details - Baiotai was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on February 21, 2020, with an issuance price of 32.76 yuan per share [1] - The total number of shares issued was 60 million, with China International Capital Corporation as the sponsor and representatives being Xie Xianming and Zhao Zeyu [1] - The stock reached a peak price of 78.00 yuan per share on its first trading day [1] Group 2: Fundraising and Financials - The total amount raised from the IPO was 1.966 billion yuan, with a net amount of 1.876 billion yuan after deducting issuance costs [1] - The net fundraising amount was 124 million yuan less than the original plan of 2 billion yuan [1] - The prospectus released on February 17, 2020, indicated that the funds were intended for drug research and development, marketing network construction, and to supplement working capital [1] Group 3: Issuance Costs - The total issuance costs for the IPO amounted to 89.4002 million yuan [1] - The underwriting and sponsorship fees paid to the sponsor and joint lead underwriters (CICC, GF Securities, and Morgan Stanley Huaxin Securities) totaled 77.8302 million yuan [1]

Core Viewpoint - Baiotai's stock price has shown a year-to-date increase of 34.93%, but recent trading indicates a decline in the short term, with a notable drop of 21.45% over the past 60 days [2] Company Overview - Baiotai Biopharmaceutical Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on July 28, 2003, with its listing date on February 21, 2020 [2] - The company focuses on the research and production of innovative drugs and biosimilars, with its main business revenue composition being: 91.90% from drug sales, 6.55% from licensing, 0.90% from contract manufacturing, and 0.65% from technical services [2] Financial Performance - For the period from January to September 2025, Baiotai achieved an operating income of 684 million yuan, representing a year-on-year growth of 17.57%, while the net profit attributable to shareholders was -224 million yuan, reflecting a year-on-year increase of 38.72% [2] Stock Market Activity - As of November 17, Baiotai's stock price was 26.15 yuan per share, with a trading volume of 13.01 million yuan and a turnover rate of 0.12%, resulting in a total market capitalization of 10.828 billion yuan [1] - The net outflow of main funds was 120,900 yuan, with large single purchases amounting to 588,900 yuan (4.53% of total) and sales of 709,800 yuan (5.45% of total) [1] Shareholder Information - As of September 30, 2025, the number of Baiotai's shareholders was 9,397, a decrease of 0.89% from the previous period, with an average of 44,065 circulating shares per person, an increase of 0.89% [2] - Hong Kong Central Clearing Limited is the tenth largest circulating shareholder, holding 6.0247 million shares as a new shareholder [2]

证券代码：688177 证券简称：百奥泰 公告编号：2025-068 百奥泰生物制药股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 24 日 （星期一） 09:00-10:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 17 日（星期一）至 11 月 21 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 IR@bio-thera.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 百奥泰生物制药股份有限公司（以下简称"公司"）已于 2025 年 10 月 29 日 发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、 ...

Core Points - The stock price of Baiotai increased by 2.03% on November 12, reaching 26.59 yuan per share, with a total market capitalization of 11.01 billion yuan [1] - Baiotai's stock has risen by 37.20% year-to-date, but has seen a decline of 1.52% over the past 20 days and 14.25% over the past 60 days [1] Financial Performance - For the period from January to September 2025, Baiotai achieved a revenue of 684 million yuan, representing a year-on-year growth of 17.57% [2] - The net profit attributable to the parent company was -224 million yuan, showing a year-on-year increase of 38.72% [2] Shareholder Information - As of September 30, 2025, the number of shareholders for Baiotai was 9,397, a decrease of 0.89% from the previous period [2] - The average number of circulating shares per shareholder increased by 0.89% to 44,065 shares [2] - Hong Kong Central Clearing Limited is the tenth largest circulating shareholder, holding 6.02 million shares as a new shareholder [2] Company Overview - Baiotai Biopharmaceutical Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on July 28, 2003, with its listing date on February 21, 2020 [1] - The company's main business involves the research, development, and production of innovative drugs and biosimilars, with 91.90% of its revenue coming from drug sales [1]

Core Insights - Baiyao Tai Biopharmaceutical (Guangzhou) Co., Ltd. has been established with a registered capital of 330 million yuan, focusing on drug contract manufacturing and production [1][2] Company Information - The company is wholly owned by Baiyao Tai (688177) [1] - The legal representative is Jin Weifeng, and the company is currently in operation [2] - The registered address is located in Huangpu District, Guangzhou, Guangdong Province [2] Financial Details - The registered capital is 330 million yuan, equivalent to approximately 33 million [1][2] - The company is classified as a foreign-invested limited liability company [2] Business Scope - The operational scope includes drug contract manufacturing and drug production [1][2]

Group 1 - The establishment of Bai'ao Tai Biopharmaceutical (Guangzhou) Co., Ltd. has been recently reported, with a registered capital of 330 million yuan [1] - The company's business scope includes entrusted drug production and drug manufacturing [1] - Bai'ao Tai Biopharmaceutical is fully owned by Bai'ao Tai [1]

Group 1 - The establishment of Bai'ao Tai Biopharmaceutical (Guangzhou) Co., Ltd. has been reported, with a registered capital of 330 million yuan [1] - The company's business scope includes contract manufacturing of pharmaceuticals and pharmaceutical production [1] - Bai'ao Tai Biopharmaceutical (Guangzhou) is wholly owned by Bai'ao Tai (688177) [1]

Group 1 - The core viewpoint of the news is that Baiotai Biopharmaceutical Co., Ltd. has seen a stock price increase of 5.38%, reaching 27.80 yuan per share, with a total market capitalization of 11.511 billion yuan [1] - Baiotai's main business involves the research and development, production of innovative drugs and biosimilars, with the revenue composition being 91.90% from drug sales, 6.55% from licensing, 0.90% from processing, and 0.65% from technical services [1] Group 2 - From the perspective of fund holdings, Penghua Fund has a significant position in Baiotai, with the Penghua Anze Mixed A fund holding 600 shares, accounting for 0.02% of the fund's net value [2] - The Penghua Anze Mixed A fund has a total scale of 13.306 million yuan and has achieved a year-to-date return of 2.53% [2] Group 3 - The fund managers of Penghua Anze Mixed A include Zhu Song, Zhang Jingxian, and Shi Yunchao, with Zhu Song having a tenure of 11 years and 255 days, managing assets totaling 27.86 billion yuan [3] - The best fund return during Zhu Song's tenure is 106.13%, while the worst is 0.86% [3]

Market Overview - The biopharmaceutical sector increased by 0.7% on October 29, with C禾元 leading the gains [1] - The Shanghai Composite Index closed at 4016.33, up 0.7%, while the Shenzhen Component Index closed at 13691.38, up 1.95% [1] Top Gainers in Biopharmaceutical Sector - C禾元 (688765) closed at 113.22, with a significant increase of 24.28% and a trading volume of 208,800 shares, amounting to 2.171 billion yuan [1] - 奥浦迈 (688293) closed at 62.11, rising by 9.97% with a trading volume of 24,900 shares, totaling 149 million yuan [1] - 吴帆生物 (301393) closed at 54.59, up 5.06% with a trading volume of 45,800 shares, amounting to 244 million yuan [1] Other Notable Performers - 诺思兰德 (920047) closed at 25.93, increasing by 4.09% with a trading volume of 52,000 shares, totaling 130 million yuan [1] - 沃森生物 (300142) closed at 11.78, up 3.79% with a trading volume of 521,600 shares, amounting to 614 million yuan [1] - 三生国健 (688336) closed at 61.72, increasing by 3.52% with a trading volume of 86,900 shares, totaling 526 million yuan [1] Decliners in Biopharmaceutical Sector - 百奧泰 (688177) closed at 26.70, down 2.52% with a trading volume of 21,700 shares, totaling 57.768 million yuan [2] - 派林生物 (000403) closed at 15.73, decreasing by 2.30% with a trading volume of 159,000 shares, amounting to 251 million yuan [2] - 康华生物 (300841) closed at 74.59, down 2.06% with a trading volume of 27,800 shares, totaling 208 million yuan [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 399 million yuan from institutional investors, while retail investors saw a net inflow of 331 million yuan [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are actively buying [2][3] Individual Stock Capital Flow - 辽宁成大 (600739) had a net inflow of 38.8721 million yuan from institutional investors, while retail investors had a net outflow of 15.3175 million yuan [3] - C禾元 (688765) saw a net inflow of 36.5446 million yuan from institutional investors, with retail investors experiencing a net outflow of 62.1427 million yuan [3] - 康弘药业 (002773) had a net inflow of 19.6335 million yuan from institutional investors, while retail investors faced a net outflow of 26.8166 million yuan [3]